Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Cell Host & Microbe|August 12, 2017
Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1Yoshiaki Nishimura, Malcolm A MartinCurrent Opinion in Virology|September 13, 2011
The acute HIV infection: implications for intervention, prevention and development of an effective AIDS vaccineYoshiaki Nishimura, Malcolm A MartinPlos One|November 2, 2011
The simian immunodeficiency virus targets central cell cycle functions through transcriptional repression in vivoCarl-Magnus Hogerkorp, Yoshiaki Nishimura, Kaimei Song, et al.AIDS Research and Human Retroviruses|January 12, 2010
Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assayRonald Willey, Martha C Nason, Yoshiaki Nishimura, et al.Nature|March 29, 2005
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infectionJoseph J Mattapallil, Daniel C Douek, Brenna Hill, et al.Journal of Virology|September 5, 2002
Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virusYuko Goto, Yoshiaki Nishimura, Kenji Baba, et al.Journal of Virology|March 23, 2007
Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDSCharles R Brown, Meggan Czapiga, Juraj Kabat, et al.Journal of Virology|May 31, 2013
Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoproteinReza Sadjadpour, Olivia K Donau, Masashi Shingai, et al.Journal of Virology|February 12, 2002
Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesYoshiaki Nishimura, Tatsuhiko Igarashi, Nancy Haigwood, et al.Journal of Virology|May 8, 2009
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent diseaseMakoto Kubo, Yoshiaki Nishimura, Masashi Shingai, et al.Pageof 6